Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy

Steffen Rosen, Stefan Tiefenbacher, Mary Robinson, Mei Huang, Jaydeep Srimani, Donnie Mackenzie, Terri Christianson, K. John Pasi, Savita Rangarajan, Emily Symington, Adam Giermasz, Glenn F. Pierce, Benjamin Kim, Stephen J. Zoog, Christian Vettermann

Blood (2020) 136 (22): 2524–2534.

https://doi.org/10.1182/blood.2020005683

Published: 2020

Includes: Supplemental data

Journal Articles

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Blood (2020) 135 (17): 1484–1496.

https://doi.org/10.1182/blood.2019001292

Published: 2020

Includes: Supplemental data

Journal Articles

Novel Structural Variants Originating in F8 N on-Coding Regions in Previously Unresolved Cases of Severe Hemophilia A

Marsha M Wheeler, PhD, Barbara A Konkle, Crystal Watson, Glenn F. Pierce, Deborah A Nickerson, Jill M Johnsen, MD

Blood (2018) 132 (Supplement 1): 379.

https://doi.org/10.1182/blood-2018-99-112690

Published: 2018

Journal Articles

Interim Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in a Phase-1/2 Clinical Study of Bmn 270, an AAV5-Mediated Gene Therapy for Hemophilia a

Brian Long, PhD MS, BSMedTech, Benjamin Kim, Wing Yen Wong, Ke Yang, Christian Vettermann, Nancy Pryer, Romain Hardet, Klaudia Kuranda, Philippe Veron, Federico Mingozzi, Glenn F. Pierce, Becky Schweighardt

Blood (2017) 130 (Supplement 1): 4611.

https://doi.org/10.1182/blood.V130.Suppl_1.4611.4611

Published: 2017

Journal Articles

Achievement of Normal Circulating Factor VIII Activity Following Bmn 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia a

K. John Pasi, Savita Rangarajan, Benjamin Kim, Will Lester, David Perry, Bella Madan, Fatemeh Tavakkoli, Ke Yang, Glenn F. Pierce, Wing Yen Wong

Blood (2017) 130 (Supplement 1): 603.

https://doi.org/10.1182/blood.V130.Suppl_1.603.603

Published: 2017

Journal Articles

Novel Approach to and Results of Genetic Analysis of 3000 Hemophilia Patients Enrolled in the MyLifeOurFuture Initiative

Jill Johnsen, Shelley N Fletcher, Haley Huston, Sarah Roberge, Beth K Martin, Martin Kircher, Neil C Josephson, Jay Shendure, Sarah Ruuska, Marion A Koerper, Leslie Meltzer, Glenn F Pierce, Diane Aschman, Pharm D, Barbara Konkle, MD

Blood (2016) 128 (22): 205.

https://doi.org/10.1182/blood.V128.22.205.205

Published: 2016

Journal Articles

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

K John Pasi, David J Perry, Johnny Mahlangu, Barbara A Konkle, MD, Savita Rangarajan, Simon Brown, Hideji Hanabusa, Shannon Jackson, Ingrid Pabinger, Lynda M Cristiano, Yingwen Dong, Elisa Tsao, Glenn F Pierce, Geoffrey Allen

Blood (2015) 126 (23): 1087.

https://doi.org/10.1182/blood.V126.23.1087.1087

Published: 2015

Journal Articles

Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study

Johnny Mahlangu, Amy D Shapiro, MD, K John Pasi, Margaret V Ragni, Margareth Castro Ozelo, MD PhD, Johannes Oldenburg, Tadashi Matsushita, MD PhD, Ross I Baker, MD, Huixing Yuan, Alejandra Ramirez-Santiago, Glenn F Pierce, Geoffrey Allen, Baisong Mei

Blood (2015) 126 (23): 1088.

https://doi.org/10.1182/blood.V126.23.1088.1088

Published: 2015

Journal Articles

Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXFc: Interim Results of the B-YOND Extension Study

Roshni Kulkarni, Beatrice Nolan, Carolyn M. Bennett, Kathelijn Fischer, David J Perry, Christopher Barnes, Huixing Yuan, Alejandra Ramirez-Santiago, Glenn F Pierce, Baisong Mei

Blood (2015) 126 (23): 1093.

https://doi.org/10.1182/blood.V126.23.1093.1093

Published: 2015

Journal Articles

Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes

Jerry S Powell, MD, Margareth Ozelo, MD PhD, Margaret V. Ragni, MD MPH, John Pasi, MBChB, PhD FRCP, FRCPath, David J. Perry, MD PhD FRCP, FRCPath, Ying Zhu, MPH, Baisong Mei, MD PhD, Glenn F Pierce, MD PhD, Lian Li, PhD, Brian Robinson, MD

Blood (2014) 124 (21): 2842.

https://doi.org/10.1182/blood.V124.21.2842.2842

Published: 2014

Journal Articles

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)

Guy Young, MD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Roshni Kulkarni, MD, Beatrice Nolan, MB, MRCPI, FRCPATH, Raina Liesner, MA MBBChir MDFRCP FRCPath MRCPCH, John Pasi, MBChB, PhD FRCP, FRCPath, Christopher Barnes, MB BS, Srividya Neelakantan, PhD, Giulia Gambino, MSc, Lynda M Cristiano, MD, Christopher Barnowski, MD, Glenn F Pierce, MD PhD, Geoffrey A. Allen, MD

Blood (2014) 124 (21): 1494.

https://doi.org/10.1182/blood.V124.21.1494.1494

Published: 2014

Journal Articles

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

Doris V. Quon, MD PhD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Amy D Shapiro, John Pasi, MBChB, PhD FRCP, FRCPath, Ying Zhu, MPH, Glenn F Pierce, MD PhD, Lian Li, PhD, Geoffrey Allen, MD

Blood (2014) 124 (21): 1522.

https://doi.org/10.1182/blood.V124.21.1522.1522

Published: 2014

Journal Articles

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Blood (2014) 123 (3): 317–325.

https://doi.org/10.1182/blood-2013-10-529974

Published: 2014

Includes: Supplemental data

Journal Articles

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

John Pasi, MBChB, PhD, FRCP, FRCPath, James Potts, Ph.D, MPH, Shuanglian Li, Ph.D., Ping Wang, Ph.D., Sarah Kulke, M.D., Glenn F Pierce, MD, PhD, Haiyan Jiang, PhD

Blood (2013) 122 (21): 3590.

https://doi.org/10.1182/blood.V122.21.3590.3590

Published: 2013

Journal Articles

Dosing Long-Lasting Recombinant Factor VIII Fc Fusion Protein: Experience In The A-LONG Study

Amy Shapiro, MD, Margaret V. Ragni, MD, MPH, Roshni Kulkarni, MD, Sarah Kulke, M.D., James Potts, Ph.D, MPH, Srividya Neelakantan, Ph.D., Ivan Nestorov, Ph.D., Jennifer A Dumont, PhD, Haiyan Jiang, PhD, Aoife Brennan, MB, BCh, BAO, MMSC, Glenn F Pierce, MD, PhD

Blood (2013) 122 (21): 3598.

https://doi.org/10.1182/blood.V122.21.3598.3598

Published: 2013

Journal Articles

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Kathelijn Fischer, MD, PhD, Roshni Kulkarni, MD, Myles Bradbury, MD, Margaret V. Ragni, MD, MPH, Savita Rangarajan, MBBS, FRCP, FRCPath, Yingwen Dong, PhD, Shuanglian Li, MD, PhD, Haiyan Jiang, PhD, Karen Nugent, MSc, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 3599.

https://doi.org/10.1182/blood.V122.21.3599.3599

Published: 2013

Journal Articles

Pharmacokinetics Of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Pediatric Subjects With Hemophilia A: An Interim Analysis Of The Kids A-LONG Study

Guy Young, MD, Johnny Mahlangu, MD, Beatrice Nolan, MB, MRCPI, FRCPATH, Simon Brown, MD, FRACP, FRCPA, MBBS, FRCP, FRCPath, Leonard A. Valentino, MD, FAAP, Raina Liesner, MA, MBBChir, MD, FRCP, FRCPath, MRCPCH, Yingwen Dong, PhD, Lei Diao, PhD, Haiyan Jiang, PhD, Karen Nugent, MSc, Glenn F. Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 3609.

https://doi.org/10.1182/blood.V122.21.3609.3609

Published: 2013

Journal Articles

Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

Amy Shapiro, MD, James Potts, Ph.D, MPH, Shuanglian Li, Ph.D., Leonard A. Valentino, MD, FAAP, Lei Diao, PhD, Ping Wang, Ph.D., Brian Robinson, M.D., Glenn F Pierce, MD, PhD, Haiyan Jiang, PhD

Blood (2013) 122 (21): 2349.

https://doi.org/10.1182/blood.V122.21.2349.2349

Published: 2013

Journal Articles

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Amy Shapiro, MD, John Pasi, MBChB, PhD, FRCP, FRCPath, Johnny Mahlangu, MD, David J. Perry, MD, PhD, FRCP, FRCPath, Jerry S Powell, MD, Margaret V. Ragni, MD, MPH, Leonard A. Valentino, MD, FAAP, Margareth Ozelo, MD, PhD, Karen Nugent, MSc, Shuanglian Li, MD, PhD, Aoife Brennan, MB, BCh, BAO, MMSC, Glenn F Pierce, MD, PhD, Geoffrey Allen, MD

Blood (2013) 122 (21): 2350.

https://doi.org/10.1182/blood.V122.21.2350.2350

Published: 2013

Journal Articles

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

Jennifer A. Dumont, Tongyao Liu, Susan C. Low, Xin Zhang, George Kamphaus, Paul Sakorafas, Cara Fraley, Douglas Drager, Thomas Reidy, Justin McCue, Helen W. G. Franck, Elizabeth P. Merricks, Timothy C. Nichols, Alan J. Bitonti, Glenn F. Pierce, Haiyan Jiang

Blood (2012) 119 (13): 3024–3030.

https://doi.org/10.1182/blood-2011-08-367813

Published: 2012

Includes: Supplemental data

NARROW

Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Novel Structural Variants Originating in F8 N on-Coding Regions in Previously Unresolved Cases of Severe Hemophilia A

Interim Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in a Phase-1/2 Clinical Study of Bmn 270, an AAV5-Mediated Gene Therapy for Hemophilia a

Achievement of Normal Circulating Factor VIII Activity Following Bmn 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia a

Novel Approach to and Results of Genetic Analysis of 3000 Hemophilia Patients Enrolled in the MyLifeOurFuture Initiative

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study

Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXFc: Interim Results of the B-YOND Extension Study

Predicting FIX Activity in Prophylaxis Patients Using Recombinant FIX Fc Fusion Protein for Treatment of Bleeding Episodes

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)

Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

Dosing Long-Lasting Recombinant Factor VIII Fc Fusion Protein: Experience In The A-LONG Study

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Pharmacokinetics Of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Pediatric Subjects With Hemophilia A: An Interim Analysis Of The Kids A-LONG Study

Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only